Phase 4
Completed N=81
Dose-response of Albuterol in Asthmatics
Source: ClinicalTrials.gov NCT00940927 ↗Enrolled (actual)
81
Serious AEs
0.0%
Results posted
Jul 2009
Primary outcomePrimary: Effective Dose 50% (ED50) — 141 ug
Summary
The purpose of this study was to determine the lung function response after increasing doses of albuterol (a bronchodilator) in children and adults with asthma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Effective Dose 50% (ED50) |
141 | — |
| PRIMARY Effect Maximum (Emax) |
24.0 | — |
Eligibility Criteria
Eligibility Criteria:
- Well-defined history of physician diagnosed asthma
- Any ethnic background
- 8 to 65 years old
- Baseline pre-bronchodilator FEV1 of 40% to 80% predicted for age, height, and gender
- No oral corticosteroid use, emergency room visits, or hospitalizations within the previous 3 months
- Nonsmokers or less than a 5 pack-year history with no smoking in the previous year
- Normal physical exam and no confounding diseases were selected
- Able to withhold inhaled short-acting b2-agonists or inhaled anticholinergic drugs for 8 hours, oral antihistamines for 5 days, theophylline for 24 hours, and cromolyn, nedocromil, and inhaled corticosteroids for 2 hours prior to the study.
Data sourced from ClinicalTrials.gov (NCT00940927). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.